Latest Gastrointestinal cancer Stories

(Ivanhoe Newswire) -- A new study provides insight into where colon cancer may come from and possible therapeutic targets for the disease. A team of researchers are using a clinically engineered mouse model for colorectal cancer. Investigators can now use the mouse to better understand how and where colorectal cancer comes from. Colorectal cancer is the second leading cause of cancer deaths in the United States. These tumors are thought to arise from a series of mutations in intestinal...

Johns Hopkins-led research suggests endoscopic ultrasound best detects them A team of scientists led by Johns Hopkins researchers have found that more than four in 10 people considered at high risk for hereditary pancreatic cancer have small pancreatic lesions long before they have any symptoms of the deadly disease. Moreover, they report, the frequency of the abnormal precancerous lesions increases with age and that ultrasound via endoscopy is better than MRI and significantly better...

Physician-scientists from University Hospitals (UH) Case Medical Center's Seidman Cancer Center and Case Western Reserve University School of Medicine presented new research findings in 24 presentations this week at the Annual Meeting of the American Association for Cancer Research (AACR) in Chicago, Illinois. "The breadth and depth of this innovative cancer research presented at AACR is truly outstanding," says Stan Gerson, MD, Director of the Seidman Cancer Center at UH Case Medical...

Anurag Singh, PhD, assistant professor in the Department of Pharmacology and Experimental Therapeutics at Boston University School of Medicine has been invited to present his recent work on targeted therapeutics for colon cancer at the American Association of Cancer Research Annual Meeting in Chicago, IL. Singh's seminar, scheduled for Tuesday April 3rd, will be featured in the "Late-Breaking Abstracts Mini-Symposium". This highlights recent and provocative groundbreaking research in cancer...

Adding the drug cetuximab to a regimen of drugs used for the treatment of patients following surgery for stage III colon cancer did not result in improved disease-free survival, according to a study in the April 4 issue of JAMA. Patients who have surgery for removal of stage III colon cancer have a 50 percent chance of cure. Multiple trials have established the benefit of chemotherapy after surgery in reducing the recurrence risk. "Specifically, [the drugs] leucovorin, fluorouracil, and...

New Study in the Journal of the American College of Surgeons reveals how a regular walking regimen can benefit some cancer survivors Researchers have affirmed that pancreatic cancer patients can literally take a step-by-step approach to combat fatigue. A study published in the April issue of the Journal of the American College of Surgeons reports that patients who underwent an operation as part of their cancer treatment and then started a regular walking regimen experienced less fatigue...

Oesophageal cancer is a very serious form of cancer that, if not fatal, requires extensive surgery. A new study from Karolinska Institutet shows that when serious complications arise after surgery for oesophageal cancer, many patients suffer other health problems, such as breathlessness, fatigue, insomnia and eating problems, for five years afterwards. "Patients who suffer serious post-operative complications after surgery for oesophageal cancer need very close, long-term monitoring so...

A study presented today by Mayo Clinic researchers at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago identified two genes that are optimal targets to be analyzed in a new noninvasive test for colorectal cancer developed by Mayo Clinic, in collaboration with Exact Sciences Corporation. The test uses a small sample of a patient's stool to check for specific DNA changes, known as gene methylation, that occur as cancer develops. The test can quickly detect both...

Johns Hopkins investigators are testing a way to use drugs that target a cholesterol pathway to enhance the cancer-killing potential of standard chemotherapy drugs. Their tests, in mouse models of pancreatic cancer, may yield new and more effective combinations of current and possibly new anti-cancer drugs. Besides their deadly consequences, pancreatic cancer and heart disease share a connection with genetic pathways that control cholesterol and a cell signaling system known as the...

SU2C-funded study is the first to evaluate treatment based on molecular profiling of advanced pancreatic cancer The feasibility of selecting treatment based on individual molecular characteristics was demonstrated in a first-of-its kind pancreatic cancer clinical trial reported today by the Translational Genomics Research Institute (TGen) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare. The findings were announced during the American Association for Cancer Research...